156 related articles for article (PubMed ID: 15957612)
21. Alström syndrome--a case report and literature review.
Karska-Basta I; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B; Kobylarz J
Klin Oczna; 2008; 110(4-6):188-92. PubMed ID: 18655459
[TBL] [Abstract][Full Text] [Related]
22. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
Ricchi P; Meloni A; Pistoia L; Spasiano A; Spiga A; Allò M; Gamberini MR; Lisi R; Campisi S; Peluso A; Missere M; Renne S; Mangione M; Positano V; Pepe A
Ann Hematol; 2018 Oct; 97(10):1925-1932. PubMed ID: 29926157
[TBL] [Abstract][Full Text] [Related]
23. Electro-oculographic abnormalities in amblyopia.
Williams C; Papakostopoulos D
Br J Ophthalmol; 1995 Mar; 79(3):218-24. PubMed ID: 7703197
[TBL] [Abstract][Full Text] [Related]
24. Delayed-onset chloroquine retinopathy.
Ehrenfeld M; Nesher R; Merin S
Br J Ophthalmol; 1986 Apr; 70(4):281-3. PubMed ID: 3964626
[TBL] [Abstract][Full Text] [Related]
25. Retinal electrophysiological results in patients receiving lamotrigine monotherapy.
Arndt CF; Husson J; Derambure P; Hache JC; Arnaud B; Defoort-Dhellemmes S
Epilepsia; 2005 Jul; 46(7):1055-60. PubMed ID: 16026557
[TBL] [Abstract][Full Text] [Related]
26. Microperimetric assessment of the two optical coherence tomography subtypes of acute macular neuroretinopathy.
Battaglia Parodi M; Iacono P; Panico D; Cascavilla M; Bandello F
Clin Exp Ophthalmol; 2015; 43(7):637-42. PubMed ID: 25752249
[TBL] [Abstract][Full Text] [Related]
27. Assessing hydroxychloroquine toxicity by the multifocal ERG.
Moschos MN; Moschos MM; Apostolopoulos M; Mallias JA; Bouros C; Theodossiadis GP
Doc Ophthalmol; 2004 Jan; 108(1):47-53. PubMed ID: 15104166
[TBL] [Abstract][Full Text] [Related]
28. Macular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient.
Angi M; Romano V; Valldeperas X; Romano F; Romano MR
Int Ophthalmol; 2010 Apr; 30(2):195-7. PubMed ID: 19165421
[TBL] [Abstract][Full Text] [Related]
29. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
30. Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa.
Obolensky A; Berenshtein E; Lederman M; Bulvik B; Alper-Pinus R; Yaul R; Deleon E; Chowers I; Chevion M; Banin E
Free Radic Biol Med; 2011 Oct; 51(8):1482-91. PubMed ID: 21824515
[TBL] [Abstract][Full Text] [Related]
31. Ocular toxicity of high-dose intravenous desferrioxamine.
Davies SC; Marcus RE; Hungerford JL; Miller MH; Arden GB; Huehns ER
Lancet; 1983 Jul; 2(8343):181-4. PubMed ID: 6135026
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
33. Retinal pigment epithelial dysfunction in human immunodeficiency virus-infected patients with cytomegalovirus retinitis.
Harrison JM; van Heuven WA
Ophthalmology; 1999 Apr; 106(4):790-7. PubMed ID: 10201604
[TBL] [Abstract][Full Text] [Related]
34. [Electroretinogram and electrooculogram in a family with Stargardt's disease].
Pojda-Wilczek D; Makowiecka-Obidzińska K; Herba E
Klin Oczna; 2004; 106(3 Suppl):540-1. PubMed ID: 15636262
[TBL] [Abstract][Full Text] [Related]
35. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
36. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
37. HIF2α activation and mitochondrial deficit due to iron chelation cause retinal atrophy.
Kong Y; Liu PK; Li Y; Nolan ND; Quinn PMJ; Hsu CW; Jenny LA; Zhao J; Cui X; Chang YJ; Wert KJ; Sparrow JR; Wang NK; Tsang SH
EMBO Mol Med; 2023 Feb; 15(2):e16525. PubMed ID: 36645044
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Browning DJ
Am J Ophthalmol; 2002 May; 133(5):649-56. PubMed ID: 11992862
[TBL] [Abstract][Full Text] [Related]
39. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
[TBL] [Abstract][Full Text] [Related]
40. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
